{"commentary":{"count":111,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":62,"podcast":27,"x_thread":21,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05257083\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CARTITUDE-6","nct_id":"NCT05257083","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cartitude-6-nct05257083. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CARTITUDE-6","arms":[{"description":"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 4 induction cycles. Followed by ASCT and 2 cycles of DVRd consolidation, and lenalidomide maintenance therapy for 2 years\n\nDaratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.\n\nBortezomib SC 1.3 mg/m\\^2 on days 1, 4, 8, and 11 of each cycle 1-6. Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6. Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.\n\nEach cycle will consist 28 days.\n\nLenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years","label":"Arm A: DVRd + ASCT+DVRd (Standard Therapy)","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 6 induction cycles.\n\nParticipants will receive a conditioning regimen (cyclophosphamide 300 mg/m\\^2 intravenous \\[IV\\] and fludarabine 30 mg/m\\^2 IV daily for 3 days) and Cilta-cel infusion 0.75\\*10\\^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg), followed by lenalidomide post CAR-T cell therapy for 2 years\n\nDaratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.\n\nBortezomib SC 1.3 mg/m\\^2 on days 1, 4, 8, and 11 of each cycle 1-6.\n\nLenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6.\n\nDexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.\n\nEach cycle will consist of 28 days.\n\nLenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years","label":"Arm B: DVRd followed by Ciltacabtagene Autoleucel","type":"EXPERIMENTAL"}],"collaborators":["Janssen Research & Development, LLC"],"completion_date":{"date":"2040-08","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":759,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Daratumumab","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Cilta-cel","type":"DRUG"},{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Fludarabine","type":"DRUG"}],"last_update":"2026-03-17","lead_sponsor":"Stichting European Myeloma Network","official_title":"A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"up to 10 years ( or 300 PFS events)"},{"measure":"Sustained MRD-negative CR","timeFrame":"up to 24 months"}],"references":[],"start_date":{"date":"2023-10-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05257083"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cartitude-6-nct05257083"}